Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia

Acta Obstetricia et Gynecologica Scandinavica

Volumn 78, Issue 3, 1999, Pages 191-197

  Schjetlein, Rune ^a,b   Abdelnoor, Michael ^b   Haugen, Guttorm ^a   Husby, Henrik ^a   Sandset, Per Morten ^a   Wisløff, Finn ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Coagulation; Fetal growth retardation; Fibrinolysis; Preeclampsia

Indexed keywords

ANTITHROMBIN; BINDING PROTEIN; BLOOD CLOTTING FACTOR 7; FIBRIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN S; THROMBIN ANTITHROMBIN COMPLEX; TISSUE FACTOR PATHWAY INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; FEMALE; FIBRIN DEPOSITION; FIBRINOLYSIS; HUMAN; INTRAUTERINE GROWTH RETARDATION; LIPID METABOLISM; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033055663     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1080/j.1600-0412.1999.780304.x     Document Type: Article

References (23)

1. The hypertensive disorders of pregnancy. World Health Organization Technical Report Series 758. Geneva: World Health Organization, 1987.
2. Bonnar J, McNicol GP, Douglas AS. Coagulation and fibrinolytic systems in preeclampsia and eclampsia. Br Med J 1971; 2: 12-16.
3. Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogén activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74: 1332-8.
4. Thornton JG, Molloy BJ, Vinall PS, Philips PR, Hughes R, Davies JA. A prospective study of haemostatic tests at 28 weeks gestation as predictors of preeclampsia and growth retardation. Thromb Haemost 1989; 61: 243-5.
5. Schjetlein R, Haugen G, Wisløff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Acta Obstet Gynecol Scand 1997; 76: 541-6.
6. Schjetlein R, Haugen G, Sandset PM, Wisløff F. Reduced C4b-binding protein in preeclampsia. Thromb Res 1987; 85: 153-8.
7. Bjerkedal T, Bakketeig L, Lehmann EH. Percentiles of birth weights of single, live births at different gestational periods. Acta Pædiatr Scand 1973; 62: 449-57.
8. Østergaard PB, Beck TC, Ørsted H, Svendsen A, Nordfang O, Sandset PM et al. An enzyme linked immunosorption assay for tissue factor pathway inhibitor. Thromb Res 1997; 87: 447-59.
9. Kleinbaum DG, Kopper LL, Morgenstern H. Epidemiologic Research, Principles and Quantitative Methods. New York: Van Nostrand Reinhold, 1982.
10. Cadroy Y, Grandjean H, Pichon J, Desprats R, Berrebi A, Furnié A et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol 1993; 100: 416-20.
11. De Boer K, Ten Cate JW, Sturk A, Borm JJJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989; 160: 95-100.
12. Weenink GH, Treffers PE, Vijn P, Smorenberg-Schoorl ME, Ten Cate JW. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity. Am J Obstet Gynecol 1984; 148: 1092-7.
13. Sandset PM. Tissue factor pathway inhibitor (TFPI) - an update. Haemostasis 1996; 26 (Suppl 4): 154-65.
14. Kemkes-Matthes B. Acquired protein S deficiency. Clin Invest 1992; 70: 529-34.
15. Lindoff C, Lecander I, Åstedt B. Fibrinolytic components in individual consecutive plasma samples during normal pregnancy. Fibrinolysis 1993; 7: 190-4.
16. Caron C, Goudemand J, Marey A, Beague D, Ducroux G, Drouvin F. Are haemostatic and fibrinolytic parameters predictors of preeclampsia in pregnancy-associated hypertension? Thromb Haemost 1991; 66: 410-14.
17. Estellés A, Gilabert J, España F, Aznar J, Galbis M. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Am J Obstet Gynecol 1991; 165: 138-42.
18. De Boer K, Lecander I, Ten Cate JW, Borm JJJ, Treffers PE. Placental-type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol 1988; 158: 518-22.
19. Sattar N, Gaw A, Packard CJ, Greer IA. Potential pathogenic roles of aberrant lipoprotein and fat acid metabolism in pre-eclampsia. Br J Obstet Gynaecol 1996; 103: 614-20.
20. Van Den Elzen HJ, Wladimiroff JW, Cohen-Overbeek TE, De Bruijn AJ, Grobbee DE. Serum lipids in early pregnancy and risk of pre-eclampsia. Br J Obstet Gynaecol 1996; 103: 117-22.
21. 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 1993; 70: 301-6.
22. Laurini R, Laurin J, Marŝàl K. Placental histology and fetal blood flow in intrauterine growth retardation. Acta Obstet Gynecol Scand 1994; 73: 529-34.
23. Rössner S, Öhlin A. Maternal body weight and relation to birth weight. Acta Obstet Gynecol Scand 1990; 69: 475-8.